Medtronic receives fda approval for its next generation micra leadless pacing systems

New pacemakers offer 40% more battery life,1 extend medtronic legacy of pacing leadership dublin , may 1, 2023 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, today announced it has received u.s. food and drug administration (fda) approval of its micra™ av2 and micra™ vr2, the next generation of its industry-leading miniaturized, leadless pacemakers. micra av2 and micra vr2, the world's smallest pacemakers, provide longer battery life and easier programming than prior micra pacemakers, while still delivering the many benefits of leadless pacing such as reduced complications compared to traditional pacemakers.2 with approximately 40% more battery life compared to previous generations,1 the median projected battery life of micra av2 and micra vr2 is nearly 16 and 17 years, respectively.3 this means more than 80% of patients who receive a micra are projected to only need one device for life.3 the new micra av2 also includes advanced algorithms that automatically program av synchrony, thereby coordinating the heart's upper and lower chambers.
MDT Ratings Summary
MDT Quant Ranking